This report was first published by Endpoints News. To see the original version, click here
While antibody-drug conjugates have had their moment in the sun for the past few years, a degrader twist on the hot cancer modality is gathering steam.
Roche is further delving into its decade-long partnership with C4 Therapeutics in a new collaboration that seeks to create degrader-antibody conjugates, or DACs, for treating cancers. The expanded tie-up, disclosed Thursday morning, includes $20 million upfront and the potential for about $1 billion if various milestones are hit across discovery, development and commercial stages.
您已阅读19%（624字），剩余81%（2646字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。